Clinical applications of the genomic landscape of aggressive non-Hodgkin lymphoma

Journal of Clinical Oncology

Volumn 35, Issue 9, 2017, Pages 955-962

  Moffitt, Andrea B ^a   Dave, Sandeep S ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOCAL ADHESION KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; MAMMALIAN TARGET OF RAPAMYCIN; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; STAT PROTEIN;

ANAPLASTIC LARGE CELL LYMPHOMA; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER PROGNOSIS; CUTANEOUS T CELL LYMPHOMA; DIFFUSE LARGE B CELL LYMPHOMA; ENTEROPATHY ASSOCIATED T CELL LYMPHOMA; EPIGENETICS; GENE MUTATION; GENOMICS; HEPATOSPLENIC T CELL LYMPHOMA; HODGKIN DISEASE; HUMAN; MANTLE CELL LYMPHOMA; MOLECULAR THERAPY; NEXT GENERATION SEQUENCING; NONHODGKIN LYMPHOMA; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T CELL LEUKEMIA; GENETICS; LYMPHOMA, NON-HODGKIN; METABOLISM; MOLECULARLY TARGETED THERAPY; MUTATION; PROCEDURES;

GENOMICS; HUMANS; LYMPHOMA, NON-HODGKIN; MOLECULAR TARGETED THERAPY; MUTATION; SIGNAL TRANSDUCTION;

EID: 85016248989     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.71.7603     Document Type: Review

References (67)

1. Swerdlow SH, Campo E, Pileri SA, et al: The 2016 revision of the World Health Organization (WHO) classification of lymphoid neoplasms. Blood 127:2375-2390, 2016
2. Alizadeh AA, Eisen MB, Davis RE, et al: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511, 2000
3. Rosenwald A, Wright G, Chan WC, et al: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937-1947, 2002
4. Wright G, Tan B, Rosenwald A, et al: A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 100:9991-9996, 2003
5. Hunt KE, Reichard KK: Diffuse large B-cell lymphoma. Arch Pathol Lab Med 132:118-124, 2008
6. Lossos IS, Czerwinski DK, Alizadeh AA, et al: Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 350:1828-1837, 2004
7. Hummel M, Bentink S, Berger H, et al: A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 354:2419-2430, 2006
8. Monti S, Savage KJ, Kutok JL, et al: Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 105:1851-1861, 2005
9. Lenz G, Wright G, Dave SS, et al: Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 359:2313-2323, 2008
10. Zhang J, Grubor V, Love CL, et al: Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci USA 110:1398-1403, 2013
11. Pasqualucci L, Trifonov V, Fabbri G, et al: Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 43:830-837, 2011
12. Lohr JG, Stojanov P, Lawrence MS, et al: Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by wholeexome sequencing. Proc Natl Acad Sci U S A 109:3879-3884, 2012
13. Morin RD, Mendez-Lago M, Mungall AJ, et al: Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476:298-303, 2011
14. Dave SS, Fu K, Wright GW, et al: Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 354:2431-2442, 2006
15. Love C, Sun Z, Jima D, et al: The genetic landscape of mutations in Burkitt lymphoma. Nat Genet 44:1321-1325, 2012
16. Richter J, Schlesner M, Hoffmann S, et al: Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet 44:1316-1320, 2012
17. Schmitz R, Young RM, Ceribelli M, et al: Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 490:116-120, 2012
18. Zhang J, Jima D, Moffitt AB, et al: The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells. Blood 123:2988-2996, 2014
19. Beà S, Valdés-Mas R, Navarro A, et al: Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci U S A 110:18250-18255, 2013
20. Kridel R, Meissner B, Rogic S, et al: Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood 119:1963-1971, 2012
21. Meissner B, Kridel R, Lim RS, et al: The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma. Blood 121:3161-3164, 2013
22. Gunawardana J, Chan FC, Telenius A, et al: Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma. Nat Genet 46:329-335, 2014
23. Reichel J, Chadburn A, Rubinstein PG, et al: Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. Blood 125:1061-1072, 2015
24. Vose J, Armitage J, Weisenburger D: International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes. J Clin Oncol 26:4124-4130, 2008
25. Iqbal J, Weisenburger DD, Chowdhury A, et al: Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic gd T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro. Leukemia 25:348-358, 2011
26. Iqbal J, Wright G, Wang C, et al: Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood 123:2915-2923, 2014
27. de Leval L, Rickman DS, Thielen C, et al: The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 109:4952-4963, 2007
28. Piccaluga PP, Agostinelli C, Califano A, et al: Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation. Cancer Res 67:10703-10710, 2007
29. Xu B, Liu P: No survival improvement for patients with angioimmunoblastic T-cell lymphoma over the past two decades: A population-based study of 1207 cases. PLoS One 9:e92585, 2014
30. Morris SW, Kirstein MN, Valentine MB, et al: Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 267:316-317, 1995
31. Iqbal J, Weisenburger DD, Greiner TC, et al: Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood 115:1026-1036, 2010
32. Agnelli L, Mereu E, Pellegrino E, et al: Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma. Blood 120:1274-1281, 2012
33. Huang Y, de Reynies A, de Leval L, et al: Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type. Blood 115:1226-1237, 2010
34. Palomero T, Couronne L, Khiabanian H, et al: Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet 46:166-170, 2014
35. Sakata-Yanagimoto M, Enami T, Yoshida K, et al: Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet 46:171-175, 2014
36. Odejide O, Weigert O, Lane AA, et al: A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood 123:1293-1296, 2014
37. Yoo HY, Sung MK, Lee SH, et al: A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic Tcell lymphoma. Nat Genet 46:371-375, 2014
38. Jiang L, Gu ZH, Yan ZX, et al: Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma. Nat Genet 47:1061-1066, 2015
39. Kataoka K, Nagata Y, Kitanaka A, et al: Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet 47:1304-1315, 2015
40. Crescenzo R, Abate F, Lasorsa E, et al: Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell 27:516-532, 2015
41. [Erratum: Cancer Cell 27:744, 2015]
42. Ungewickell A, Bhaduri A, Rios E, et al: Genomic analysis of mycosis fungoides and Sezary syndrome identifies recurrent alterations in TNFR2. Nat Genet 47:1056-1060, 2015
43. Wang L, Ni X, Covington KR, et al: Genomic profiling of Sezary syndrome identifies alterations of key T cell signaling and differentiation genes. Nat Genet 47:1426-1434, 2015
44. Choi J, Goh G, Walradt T, et al: Genomic landscape of cutaneous T cell lymphoma. Nat Genet 47:1011-1019, 2015
45. da Silva Almeida AC, Abate F, Khiabanian H, et al: The mutational landscape of cutaneous T cell lymphoma and Sezary syndrome. Nat Genet 47:1465-1470, 2015
46. Nicolae A, Xi L, Pittaluga S, et al: Frequent STAT5B mutations in 78 hepatosplenic T-cell lymphomas. Leukemia 28:2244-2248, 2014
47. Roberti A, Dobay MP, Bisig B, et al: Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations. Nat Commun 7:12602, 2016
48. Nairismagi ML, Tan J, Lim JQ, etal: JAK-STAT and G-protein-coupled receptor signaling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma. Leukemia 30:1311-1319, 2016
49. Tiacci E, Trifonov V, Schiavoni G, et al: BRAF mutations in hairy-cell leukemia. N Engl J Med 364:2305-2315, 2011
50. Compagno M, Lim WK, Grunn A, et al: Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 459:717-721, 2009
51. Bea S, Zettl A, Wright G, et al: Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood 106:3183-3190, 2005
52. Dunleavy K, Pittaluga S, Czuczman MS, et al: Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 113:6069-6076, 2009
53. Goy A, Younes A, McLaughlin P, et al: Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23:667-675, 2005
54. Assouline SE, Chang J, Cheson BD, et al: Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma. Blood Cancer J 4:e251, 2014
55. Park MH, Hong JT: Roles of NF-kB in cancer and inflammatory diseases and their therapeutic approaches. Cells 5(2), 2016
56. Yen W-C, Fischer MM, Axelrod F, et al: Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency. Clin Cancer Res 21:2084-2095, 2015
57. Tolcher AW, Messersmith WA, Mikulski SM, et al: Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol 30:2348-2353, 2012
58. Shortt J, Martin BP, Newbold A, et al: Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas. Blood 121:2964-2974, 2013
59. Walsh K, McKinney MS, Love C, et al: PAK1 mediates resistance to PI3K inhibition in lymphomas. Clin Cancer Res 19:1106-1115, 2013
60. Dal Col J, Zancai P, Terrin L, et al: Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. Blood 111:5142-5151, 2008
61. Lam LT, Wright G, Davis RE, et al: Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-kB pathways in subtypes of diffuse large B-cell lymphoma. Blood 111:3701-3713, 2008
62. Küçük C, Jiang B, Hu X, et al: Activating mutations of STAT5B and STAT3 in lymphomas derived from gd-T or NK cells. Nat Commun 6:6025, 2015
63. Younes A, Romaguera J, Fanale M, et al: Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: Evidence of clinical and biologic activity in multiple lymphoma subtypes. J Clin Oncol 30:4161-4167, 2012
64. Slack-Davis JK, Martin KH, Tilghman RW, et al: Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem 282:14845-14852, 2007
65. Coiffier B, Haioun C, Ketterer N, et al: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 92:1927-1932, 1998
66. Lokhorst HM, Plesner T, Laubach JP, et al: Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med 373:1207-1219, 2015
67. Byrd JC, Furman RR, Coutre SE, et al: Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369:32-42, 2013